Distinct SNP Combinations Confer Susceptibility to Urinary Bladder Cancer in Smokers and Non-Smokers

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Schwender, Holger ^a   Selinski, Silvia ^b   Blaszkewicz, Meinolf ^b   Marchan, Rosemarie ^b   Ickstadt, Katja ^c   Golka, Klaus ^b   Hengstler, Jan G ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; GLUTATHIONE TRANSFERASE M1; HYDROLASE; MYC PROTEIN; UNCLASSIFIED DRUG;

ALLELE; APOBEC3A GENE; ARTICLE; BLADDER CANCER; BOOTSTRAPPING; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DETOXIFICATION; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GSTM1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84871407540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051880     Document Type: Article

References (71)

1. Golka K, Selinski S, Lehmann ML, Blaszkewicz M, Marchan R, et al. (2011) Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". Arch Toxicol 85: 539-554.
2. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW, (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164.
3. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, et al. (1984) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842-845.
4. Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schöps W, et al. (1996) Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22: 332-338.
5. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM, (1996) Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71: 123-126.
6. Hengstler JG, Arand M, Herrero ME, Oesch F, (1998) Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154: 47-85.
7. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, et al. (2008) Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40: 1307-1312.
8. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42: 415-419.
9. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, et al. (2010) A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42: 978-984.
10. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41: 221-227.
11. Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, et al. (2011) European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 20: 4268-4281.
12. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, et al. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41, 991-995. Erratum in: Nat Genet 41: 1156.
13. Golka K, Hermes M, Selinski S, Blaszkewicz M, Bolt HM, et al. (2009) Susceptibility to urinary bladder cancer: relevance of rs9642880[T], GSTM1 0/0 and occupational exposure. Pharmacogenet Genomics 19: 903-906.
14. Lehmann ML, Selinski S, Blaszkewicz M, Orlich M, Ovsiannikov D, et al. (2010) Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch Toxicol 84: 967-978.
15. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, et al. (2012) Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. Arch Toxicol 86: 1369-1378.
16. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, et al. (2009) Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 69: 7079-7087.
17. Vartanian J-P, Guetard D, Henry M, Wain-Hobson S, (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320: 230-233.
18. Hengstler JG, Utesch D, Steinberg P, Platt KL, Diener B, et al. (2000) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32: 81-118.
19. Strassburg CP, Lankisch TO, Manns MP, Ehmer U, (2008) Family 1 uridine-5-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability. Arch Toxicol 82: 415-433.
20. García-Closas M, Hein DW, Silverman D, Malats N, Yeager M, et al. (2011) A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 21: 231-236.
21. Selinski S, Blaszkewicz M, Lehmann ML, Ovsiannikov D, Moormann O, et al. (2011) Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 21: 673-678.
22. Lefkimmiatis K, Caratozzolo MF, Merlo P, D'Erchia AM, Navarro B, et al. (2009) p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Cancer Res 69: 8563-8571.
23. Sayan BS, Sayan AE, Yang AL, Aqeilan RI, Candi E, et al. (2007) Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc Natl Acad Sci USA 104: 10871-10876.
24. Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, et al. (1991) Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217-1228.
25. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, et al. (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
26. Bolt HM, Thier R, (2006) Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 7: 613-628.
27. Zimmermann A, Blaszkewicz M, Roth G, Seidel T, Dietrich H, et al. (2008) UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism in bladder cancer cases. J Toxicol Environ Health A 71: 911-914.
28. Golka K, Abreu-Villaca Y, Anbari Attar R, Angeli-Greaves M, Aslam M, et al. (2012) Bladder cancer documentation of causes: multilingual questionnaire "Bladder Cancer Doc". Front Biosci E4: 2709-2722.
29. Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, et al. (1996) A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 236: 184-186.
30. Krause G, Müller M, Lewalter J, Schulz T (2004) Glutathione S-transferase T1 and M1 (GSTT1, GSTM1) (genotyping). In: Angerer J, Müller, M, editors. Analyses of hazardous substances in biological materials, Vol 9, Special issue: Marker of susceptibility. Weinheim, Germany: Wiley-VCH Verlag GmbH. 183-210.
31. Steenland K, Armstrong B, (2006) An overview of methods for calculating the burden of disease due to specific risk factors. Epidemiology 17: 512-519.
32. Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, et al. (2012) Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum Mol Genet 21: 1918-1930.
33. Doll R, Peto R, (1981) The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1308.
34. Rushton L, Bagga S, Bevan R, Brown TP, Cherrie JW, et al. (2010) Occupation and cancer in Britain. Br J Cancer 102: 1428-1437.
35. Delclos GL, Lerner SP, (2008) Occupational risk factors. Scand J Urol Nephrol 42(Suppl 218): 58-63.
36. Silverman DT, Levin LI, Hoover RN, Hartge P, (1989) Occupational risks of bladder cancer in the United States: I. White men. J Natl Cancer Inst 81: 1472-1480.
37. Vineis P, Pirastu R, (1997) Aromatic amines and cancer. Cancer Causes Control 8: 346-355.
38. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP, (2008) A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol 42(Suppl 218): 64-78.
39. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, et al. (1992) The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98: 87-94.
40. Lee KH, Lee J, Ha M, Choi JW, Cho SH, et al. (2002) Influence of polymorphism of GSTM1 gene on association between glycophorin a mutant frequency and urinary PAH metabolites in incineration workers. J Toxicol Environ Health A 65: 355-363.
41. Carreón T, LeMasters GK, Ruder AM, Schulte PA, (2006) The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers. Front Biosci 11: 2889-2902.
42. Giuliani L, Ciotti M, Stoppacciaro A, Pasquini A, Silvestri I, et al. (2005) UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13: 185-191.
43. Giuliani L, Gazzaniga P, Caporuscio F, Ciotti M, Frati L, Aglianò AM, (2001) Can down-regulation of UDP-glucuronosyltransferases in the urinary bladder tissue impact the risk of chemical carcinogenesis? Int J Cancer 91: 141-143.
44. Lin GF, Guo WC, Chen JG, Qin YQ, Golka K, et al. (2005) An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 85: 502-506.
45. Zenser TV, Lakshmi VM, Hsu FF, Davis BB, (2002) Metabolism of N-acetylbenzidine and initiation of bladder cancer. Mutat Res 506-507: 29-40.
46. Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, et al. (2002) Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 156: 95-109.
47. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649-659.
48. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, et al. (2011) GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 32: 182-189.
49. Golka K, Reckwitz T, Kempkes M, Cascorbi II, Blaskewicz M, et al. (1997) N-Acetyltransferase 2 (NAT2) and glutathione S-transferase μ (GSTM1) in bladder-cancer patients in a highly industrialized area. Int J Occup Environ Health 3: 105-110.
50. Ovsiannikov D, Selinski S, Lehmann ML, Blaszkewicz M, Moormann O, et al. (2012) Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J Toxicol Environ Health A 75: 557-565.
51. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85.
52. Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK, (2002) Arylamine exposures and bladder cancer risk. Mutat Res 506-507: 21-28.
53. Puente D, Hartge P, Greiser E, Cantor KP, King WD, et al. (2006) A pooled analysis of bladder cancer case-control studies evaluating smoking in men and women. Cancer Causes Control 17: 71-79.
54. Vineis P, (2002) The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 181-182: 457-462.
55. Zhang R, Xu G, Chen W, Zhang W, (2011) Genetic polymorphisms of glutathione S-transferase M1 and bladder cancer risk: a meta-analysis of 26 studies. Mol Biol Rep 38: 2491-2497.
56. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, et al. (2001) Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 10: 1249-1252.
57. Bolm-Audorff U, Jöckel KH, Kilguss B, Pohlabeln H, Siepenkothen T (1993). Bösartige Tumoren der ableitenden Harnwege und Risiken am Arbeitsplatz. Scientific report Fb 697 from the report series of the Federal Institute for Occupational Safety and Health, Dortmund, Germany. Bremerhaven, Germany: Wissenschaftsverlag NW. In German.
58. Golka K, Bandel T, Reckwitz T, Urfer W, Bolt HM, et al. (1999) Occupational risk factors for bladder carcinoma. A case control study. Urologe A 38: 358-363. In German.
59. Guha N, Steenland NK, Merletti F, Altieri A, Cogliano V, Straif K, (2010) Bladder cancer risk in painters: a meta-analysis. Occup Environ Med 67: 568-573.
60. Golka K, Bandel T, Schlaefke S, Reich SE, Reckwitz T, et al. (1998) Urothelial cancer of the bladder in an area of former coal, iron, and steel industries in Germany: a case-control study. Int J Occup Environ Health 4: 79-84.
61. Golka K, Goebell PJ, Rettenmeier AW (2007) Bladder cancer: etiology and prevention. Dtsch Arztebl 104: A 719-723.
62. Myslak ZW, Bolt HM, Brockmann W, (1991) Tumors of the urinary bladder in painters: a case-control study. Am J Ind Med 19: 705-713.
63. Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, et al. (2004) Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 15: 759-769.
64. Cordier S, Clavel J, Limasset JC, Boccon-Gibod L, Le Moual N, et al. (1993) Occupational risks of bladder cancer in France: a multicentre case-control study. Int J Epidemiol 22: 403-411.
65. Schifflers E, Jamart J, Renard V, (1987) Tobacco and occupation as risk factors in bladder cancer: a case-control study in southern Belgium. Int J Cancer 39: 287-292.
66. Thériault G, Tremblay C, Cordier S, Gingras S, (1984) Bladder cancer in the aluminium industry. Lancet 1: 947-950.
67. Golka K, Prior V, Blaszkewicz M, Bolt HM, (2002) The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett 128: 229-241.
68. Golka K, Wiese A, Assennato G, Bolt HM, (2004) Occupational exposure and urological cancer. World J Urol 21: 382-391.
69. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, et al. (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86: 289-294.
70. Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, et al. (2001) The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 12: 411-417.
71. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, et al. (2008) Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122: 155-164.